ClinicalTrials.gg
CompletedNCT03390101BCD-085-7Updated Jun 1, 2022Results posted

An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of BCD-085 Q2W and BCD-085 Q4W in Moderate to Severe Plaque Psoriasis, sponsored by Biocad. Completed at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-01.

Sponsored by Biocad · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
213
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Psoriasis with a site in Russian Federation — 1 open to participants now, 1 under way, 1 of them phase 3. Psoriasis · Russian Federation.

Enrollment
35th of 46
213 · median 411
Started
2017
with 2 others
Phase 3
38 of 50
1 open now
Registered
39th of 50
by date
Lead sponsor
3 of 50
Biocad

Among the 50 studies in Psoriasis with a site in Russian Federation, this one is the 35th largest by enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2017, is one of 38 in phase 3, and was the 39th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 50 studies in Psoriasis with a site in Russian Federation is open now. Recruiting first, the newest first:

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Psoriasis with a site in Russian Federation, or all of them as a file.
02

Study summary

BCD-085 is an innovative drug, a monoclonal antibody against interleukin-17. The toxicity, safety, and pharmacokinetics of BCD-085 were investigated in animals, in phase I clinical study in healthy volunteers, and in phase III clinical study in patients with moderate to severe plaque psoriasis. This clinical study aims at investigating the efficacy and safety of BCD-085 every other week regimen (after induction for the first 3 weeks) versus BCD-085 one per month regimen (after induction for first 3 weeks) versus placebo in patients with moderate to severe plaque psoriasis.

Study purpose:

To investigate the efficacy and safety of BCD-085 versus placebo in patients with moderate to severe plaque psoriasis (psoriasis vulgaris)

Study objectives:

  1. To compare the efficacy of BCD-085 every 2 weeks versus BCD-085 every 4 weeks versus placebo, based on the proportion of patients who achieved a PASI75, target sPGA score, and on other secondary efficacy measures.
  2. To evaluate the proportion of patients in each study arm who develop adverse events with multiple injections of BCD-085 and placebo. Compare the safety profiles of BCD-085 when used every 4 weeks and when used every 2 weeks.
    1. To assess the immunogenicity of BCD-085 defined as the proportion of patients who develop anti-drug antibodies (binding or neutralizing).
03

Conditions studied

  • Moderate to Severe Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must give a written and signed .
  2. Men or women at least 18 years old at the time of signing the ICF
  3. Moderate to severe plaque psoriasis diagnosed at least 6 months before signing the informed consent form.
  4. Patients received at least one course of phototherapy or systemic therapy for psoriasis or are candidates for such treatment according to the investigator.
  5. Body surface area (BSA) affected by psoriasis of 10% or greater, the PASI score of 10 or greater, and the sPGA score of 3 or greater at screening.
  6. Negative pregnancy urine test in female subjects (no test is required in women who are for at least 2 years and in surgically sterile women).
  7. The patient must be able to follow the Protocol procedures (in the investigator's opinion).
  8. Patients of and their partners with preserved reproductive function must implement reliable methods starting from signing informed consent to 20 weeks after the last dose of the study therapy. This requirement does not apply to the patients after surgical sterilization and to females who are post-menopausal for 2 years or longer. Reliable contraception methods suggest using one barrier method in combination with one of the following: spermicides, intrauterine device/oral contraceptives

Exclusion criteria

Exclusion Criteria:

  1. Baseline erythrodermic, pustular, and guttate psoriasis or any other skin diseases (e.g. eczema) that can affect/complicate assessment of psoriasis treatment
  2. Use of the following medications:

    • Prior use of monoclonal antibodies targeting IL17 or its receptor
    • Prior use of more than one drug containing monoclonal antibodies or their fragments
    • Prior use of monoclonal antibodies within 12 weeks before signing the .
    • Any systemic medications for psoriasis (including , methotrexate, sulfasalazine, cyclosporine, acitretin, mycophenolate mofetil, аpremilast, calcitriol derivatives, etc.) used within 4 weeks before signing the ICF If prior systemic therapy with non-biologics was stopped due to any reasons, the screening period can be extended up to 8 weeks during which no new non-biologics are allowed.
    • Use of phototherapy within 4 weeks before signing the ICF
    • Topical medications for psoriasis used within 2 weeks before signing the ICF
    • Vaccination with live or attenuated vaccines within 8 weeks before signing the ICF
  3. Any active systemic infection or recurrent infection at screening/randomization
  4. , , , or syphilis
  5. Blood biochemistry abnormalities appearing as:

    1. baseline creatinine > 2 ×
    2. baseline , AST or alkaline phosphatase > 2.5 × ULN
    3. baseline > 1.5 × ULN
  6. WBC count \< 3.0 × 109/L; ANC \< \<2.0× 109/L; count \< 100 × 109/L, or \< 90 g/L at baseline
  7. Any psychiatric conditions including severe depressive disorders and/or any history of suicidal thoughts or suicidal attempts ;
  8. Signs of depression (Beck's score of 16 or more at screening)
  9. Alcohol or substance abuse
  10. Tuberculosis now or in the past
  11. Latent TB infection (positive results of the Diaskintest or QuantiFERON test, or T-spot).
  12. Concurrent diseases ongoing at screening that may increase the risk of adverse events during the study or affect the evaluation of psoriasis symptoms (mask, enhance or alter the symptoms of psoriasis, or cause clinical or laboratory signs/symptoms similar to those of psoriasis):

    • active inflammatory diseases or aggravation of chronic inflammatory diseases other than psoriasis
    • Stable angina class III-IV, unstable angina or a history of myocardial infarction within 1 year before signing the informed consent
    • Cardiac failure moderate to severe ( class III-IV)
    • Treatment-resistant hypertension
    • A history of severe asthma or angioedema
    • Moderate to severe respiratory failure, grade ¾
    • Diabetes mellitus with unsatisfactory glycemic control, when the level of HbA1С ≥8% (results are valid if the test was performed at the screening or within 3 months before signing the ICF)
    • The patient has thyrotoxicosis, which persists in the presence of thyreostatic medications, or hypothyroidism despite of the thyroid hormone treatment
    • Systemic diseases (including but not limited to SLE, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, systemic scleroderma, inflammatory myopathy, mixed connective tissue disease , intersection syndrome, etc.)
    • Any other underlying conditions (including but not limited to metabolic, hematologic, hepatic, renal, pulmonary, neurological, endocrine, cardiac, gastrointestinal conditions and infections) that, in the opinion of the investigator, may affect the course of psoriasis, affect the assessment of signs/symptoms of psoriasis, or put patients using the study treatment at additional risk
  13. with less than 5 years of remission
  14. Known severe allergies (anaphylaxis or drug allergy to two or more drug products)
  15. Known allergy or intolerance to monoclonal antibody drugs (murine, chimeric, humanized, or human) or any other components of the test drug or comparator
  16. Major surgery within 30 days before the screening, or a major surgery being scheduled at any time during the study
  17. Severe infections (including those that required hospitalization or parenteral antibacterial/antimycotic/antiprotozoal treatment) within 6 months before signing the ICF
  18. Systemic antibacterial/antimycotic/antiprotozoal treatment within 2 months before the signing the ICF
  19. More than 4 episodes of respiratory infection within 6 months before signing the ICF
  20. Episodes of severe mycoses (histoplasmosis, coccidioidomycosis, blastomycosis, etc.) within 6 months before signing the ICF
  21. A history of epileptic attacks or seizures
  22. Any concurrent diseases during which, in the investigator's opinion, the study treatment can harm the patient
  23. Pregnancy, breastfeeding, or planning for pregnancy while participating in the study
  24. Participation in any other clinical study within 3 months before signing the ICF or simultaneous participation in other clinical studies
  25. Patients will not be re-enrolled in this study if they were randomized to this study and then discontinue the participation
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
213 participants (actual)

Study arms

  • Experimental
    BCD-085 Q2W

    Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 1 will be given BCD-085 every 4 weeks through Week 50.

    Drug: BCD-085 Q2W

  • Experimental
    BCD-085 Q4W

    Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 6 and Day 1 of Week 10. For the purpose of blind design, patients will receive a placebo (2 injections) on day 1 of week 4 and week 8. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will continue BCD-085 every 4 weeks through Week 50.

    Drug: BCD-085 Q4W

  • Placebo comparator
    Placebo

    Patients in this arm (43 subjects) will be given two SC injections of placebo (1.0 mL each) on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2, Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 on Day 1 of Week 12, Day 1 of Week 13, Day 1 of Week 14 (induction), then every 4 weeks through Week 50.

    Drug: Placebo

Interventions

  • In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54.

    Also known as: BCD-085

  • In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54.

    Also known as: BCD-085

  • DrugPlacebo

    In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54.

06

What researchers measure

Primary outcomes

  1. • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment

    The Psoriasis Area and Severity Index (PASI) allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease). Relative (percentage) change in PASI score from baseline (screening) is calculated as 100 x (baseline value - time point t value) / (baseline value) PASI 75 indicates a 75% or greater reduction in PASI scores from baseline and is indicative of excellent disease improvement.

    Time frame: week 12

07

Results

Posted May 11, 2021

Participant flow

Weeks 0-12
Participant flow — Weeks 0-12
MilestoneBCD-085 Q2WBCD-085 Q4WPlacebo
Started858444
Completed858243
Not completed021
Withdrew: Withdrawal by subject011
Withdrew: Lost to follow-up010
Weeks 12-54
Participant flow — Weeks 12-54
MilestoneBCD-085 Q2WBCD-085 Q4WPlacebo
Started858243
Completed827841
Not completed342
Withdrew: Withdrawal by subject031
Withdrew: Pregnancy100
Withdrew: Adverse event211

Outcome measures

Primary• The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment

The Psoriasis Area and Severity Index (PASI) allows evaluating the extent and severity of skin symptoms of psoriasis. Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself and scores are combined for final PASI: 0 (no disease) to 72 (maximal disease). Relative (percentage) change in PASI score from baseline (screening) is calculated as 100 x (baseline value - time point t value) / (baseline value) PASI 75 indicates a 75% or greater reduction in PASI scores from baseline and is indicative of excellent disease improvement.

Time frame:
week 12
Reported as:
Count of participants · Participants
• The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment
ParticipantsBCD-085 Q2WBCD-085 Q4WPlacebo
• The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment66700

Adverse events

Collected over Weeks 0-12. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BCD-085 Q2W0/85 (0%)0/85 (0%)15/85 (17.6%)
BCD-085 Q4W0/84 (0%)1/84 (1.2%)13/84 (15.5%)
Placebo0/44 (0%)0/44 (0%)8/44 (18.2%)
Most frequent serious events
Most frequent serious events
EventBCD-085 Q2WBCD-085 Q4WPlacebo
PneumoniaInfections and infestations0/851/840/44
Most frequent other events
Showing 10 of 24
Most frequent other events
EventBCD-085 Q2WBCD-085 Q4WPlacebo
HyperbilirubinemiaHepatobiliary disorders4/852/841/44
Upper respiratory tract infectionInfections and infestations0/850/842/44
ProteinuriaRenal and urinary disorders1/850/842/44
HyperglycaemiaMetabolism and nutrition disorders0/853/840/44
NeutropeniaBlood and lymphatic system disorders3/851/840/44
LeukopeniaBlood and lymphatic system disorders1/852/840/44
ErythemaSkin and subcutaneous tissue disorders0/850/841/44
LymphocytosisBlood and lymphatic system disorders1/850/841/44
Blood creatinine increasedInvestigations0/850/841/44
Thermal burnInjury, poisoning and procedural complications0/850/841/44

Baseline characteristics

All randomized subjects

Age, Continuous
Age, Continuous(years)BCD-085 Q2WBCD-085 Q4WPlaceboTotal
Median42 (35 to 49)41.5 (32 to 53)39 (33 to 53)42 (33 to 52)
Sex: Female, Male
Sex: Female, Male(Participants)BCD-085 Q2WBCD-085 Q4WPlaceboTotal
Female2226957
Male635835156
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BCD-085 Q2WBCD-085 Q4WPlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White858444213
More than one race0000
Unknown or Not Reported0000
Weight
Weight(kg)BCD-085 Q2WBCD-085 Q4WPlaceboTotal
Median87.3 (75 to 96.1)89.5 (78 to 98)83.5 (70 to 95)87.3 (75 to 97)
Height
Height(cm)BCD-085 Q2WBCD-085 Q4WPlaceboTotal
Median178 (170 to 184)176 (168 to 182)175.5 (168 to 180)176 (169 to 182)
Body Surface Area Affected by Psoriasis (BSA)
Body Surface Area Affected by Psoriasis (BSA)(percentage of BSA)BCD-085 Q2WBCD-085 Q4WPlaceboTotal
Median20 (13 to 42)22 (14.5 to 43)22.5 (13 to 44)22 (14 to 43)
PASI score
PASI score(score)BCD-085 Q2WBCD-085 Q4WPlaceboTotal
Median18.4 (14.2 to 27)17.9 (15.1 to 28.6)19.7 (16.3 to 29.4)18.6 (15 to 28.5)
sPGA score
sPGA score(score)BCD-085 Q2WBCD-085 Q4WPlaceboTotal
Median3 (3 to 4)4 (3 to 4)4 (3 to 4)3 (3 to 4)
08

Study locations

1 site
  • BIOCAD
    Saint Petersburg, Strelna 198515, Russian Federation
09

References and documents

Publications

  • Puig L, Bakulev AL, Kokhan MM, Samtsov AV, Khairutdinov VR, Morozova MA, Zolkin NA, Kuryshev IV, Petrov AN, Artemeva AV, Zinkina-Orikhan AV. Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial. Dermatol Ther (Heidelb). 2021 Aug;11(4):1319-1332. doi: 10.1007/s13555-021-00554-4. Epub 2021 May 31. PubMed 34060012 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Jul 2018, 7 months.

Results were first posted in May 2021, 2 years 9 months after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2017
First posted
Jan 4, 2018
StartActual
Dec 26, 2017
Primary completionActual
Jul 30, 2018
CompletionActual
Jan 20, 2022
Results first posted
May 11, 2021
Last update
Jun 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03390101
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Jan 4, 2018
Start date
Dec 26, 2017
Primary completion
Jul 30, 2018
Completion
Jan 20, 2022
Results posted
May 11, 2021
Last update
Jun 1, 2022

Study contacts

Roman Ivanov, PhD
study chair · Vice-president, R&D, International business development BIOCAD

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BCD-085

Start the discussion